ING Groep NV lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 14.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,147 shares of the medical research company’s stock after selling 1,193 shares during the quarter. ING Groep NV’s holdings in Thermo Fisher Scientific were worth $1,352,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in TMO. Proficio Capital Partners LLC boosted its position in shares of Thermo Fisher Scientific by 71.5% in the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock worth $105,000 after purchasing an additional 253 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $113,000. Chicago Partners Investment Group LLC acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $108,000. Ropes Wealth Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 15.8% in the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock worth $124,000 after purchasing an additional 97 shares in the last quarter. Finally, Atlantic Trust LLC acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $138,000. 86.16% of the stock is currently owned by institutional investors and hedge funds.
A number of brokerages have commented on TMO. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. Barclays reaffirmed an “overweight” rating and set a $215.00 price target (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday, September 25th. Argus reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. Jefferies Group reaffirmed a “hold” rating and set a $195.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $220.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average price target of $205.21.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the transaction, the chief executive officer now owns 252,577 shares in the company, valued at approximately $47,582,981.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Inc. (TMO) traded up $2.33 during midday trading on Monday, hitting $187.96. The company’s stock had a trading volume of 2,437,700 shares, compared to its average volume of 1,564,998. The stock has a market cap of $75,371.09, a price-to-earnings ratio of 20.66, a P/E/G ratio of 1.72 and a beta of 1.06. Thermo Fisher Scientific Inc. has a twelve month low of $139.88 and a twelve month high of $201.20. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The company’s revenue was up 13.9% on a year-over-year basis. During the same quarter last year, the business posted $2.03 EPS. sell-side analysts expect that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.15 per share. The ex-dividend date is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s payout ratio is currently 10.19%.
TRADEMARK VIOLATION WARNING: This news story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/11/ing-groep-nv-sells-1193-shares-of-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related companies with MarketBeat.com's FREE daily email newsletter.